A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
← catalyst calendarSponsored by Jasper Therapeutics, Inc. (industry) · JSPR — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
27actual
Sites
5
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Enrollment was completed and primary efficacy endpoint was completed. Study was terminated before safety follow up was completed due to changes in company priorities and not related to safety concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-18 | actual | When the study began enrolling |
| Primary completion | 2025-07-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-31 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Inducible Urticaria
Intervention
- Drug: Briquilimab — also filed as JSP191
Primary outcome
what the primary-completion date above is the date OFIncidence and severity of treatment emergent AEs/SAEs [safety and tolerability] of a single dose of briquilimab in patients with ColdU or SD who remain symptomatic despite the use of H1 antihistamines.
measured From signing the informed consent form (ICF) through end of trial (EOT) visit (Week 36)
Permalink · JSPR's whole pipeline · Catalyst calendar · Every registered study · What changed